SCHEMBL2921985

SCHEMBL2921985

C[Si](C)(C)OC1CN(Cc2ccc(Cl)cc2)C1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
S1PR5 Q9H228 1/20 0.46
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
DRD4 P21917 7/20 0.42
DRD2 P14416 2/20 0.42
DRD3 P35462 2/20 0.42
TEAD1 P28347 1/20 0.42
LSS P48449 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
LTA4H P09960 2/20 0.40
GRM2 Q14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919409 0.87 S1PR1 (0.48) S1PR5ALDH1A1SIGMAR1MEN1KMT2A
SCHEMBL2919442 0.85 S1PR5 (0.44) S1PR5KDM4ESIGMAR1DRD4GRM2
SCHEMBL2921823 0.85 FUCA1 (0.50) S1PR5SIGMAR1MEN1KMT2ADRD4
SCHEMBL2912574 0.84 SMN1; SMN2 (0.54) SIGMAR1DRD4DRD2DRD3GRM2
SCHEMBL2917808 0.77 SIGMAR1 (0.52) KDM4EALDH1A1SIGMAR1MEN1KMT2A
SCHEMBL2910904 0.73 SIGMAR1 (0.57) KDM4EALDH1A1SIGMAR1MEN1KMT2A
SCHEMBL3107774 0.73 ALDH1A1 (0.52) S1PR5KDM4EALDH1A1SIGMAR1MEN1
SCHEMBL2920255 0.71 KDM4E (0.55) S1PR5KDM4EALDH1A1SIGMAR1MEN1
SCHEMBL28385966 0.71 BCHE (0.57) KDM4EALDH1A1DRD2LTA4H
SCHEMBL22731735 0.71 ALDH1A1 (0.53) S1PR5KDM4EALDH1A1SIGMAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1784407-B1 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF KOREA RES INST CHEM TECH (KR) 2010-09-08 EP disclosed
US-7662810-B2 Potassium(1R,5S,6S)-2-(1-benzyl-azetidine-3-yl-thio)-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate; antibacterial activities against Grampositive and Gramnegative bacteria and excellent antibacterial activities against resistant bacteria such as methicillin resistant Staphylococcus aureus KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-16 US disclosed
EP-1784407-A4 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF KOREA RES INST CHEM TECH (KR) 2009-02-11 EP disclosed
US-20070244089-A1 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-10-18 US disclosed
EP-1784407-A1 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF Korea Research Institute of Chemical Technology (KR) 2007-05-16 EP disclosed
WO-2006025634-A1 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244089-A1 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof SCN9A, SCN2A, SCN5A S1PR5 3459/4885KDM4E 232/4885ALDH1A1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.